Sobi and Innate announce partnership is now effective following completion of closing conditions
Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.
On the 10th of August 2026, Sobi entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL